Quest Diagnostics (DGX) EBITDA Margin (2009 - 2026)

Quest Diagnostics has disclosed EBITDA Margin across 18 years of filings, most recently posting 13.78% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 13.78%, up 74.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.27% (up 56.0% YoY), and the FY2025 annual result was 14.1%, up 47.0% from the prior year.
• EBITDA Margin came in at 13.78% for Q1 2026 at Quest Diagnostics, roughly flat from 13.76% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 19.65% in Q1 2022 to a low of 5.79% in Q4 2022.
• The 5-year median for EBITDA Margin is 13.77% (2024), against an average of 13.9%.
• Across the five-year window, EBITDA Margin sank 1375 bps in 2022 and jumped 588 bps in 2023, its largest moves.
• Quest Diagnostics' EBITDA Margin stood at 5.79% in 2022, then surged by 102 bps to 11.67% in 2023, then grew by 18 bps to 13.77% in 2024, then declined by 0 bps to 13.76% in 2025, then rose by 0 bps to 13.78% in 2026.
• The last three EBITDA Margin figures came in at 13.78% (Q1 2026), 13.76% (Q4 2025), and 13.71% (Q3 2025), per Business Quant data.